Phase l/II Study of Ruxolitinib for Acute Leukemia

NCT01251965 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Study was stopped by the principal investigator due to nonsatisfactory clinical benefit even in patients treated at the highest dose (200 mg ).

Conditions

Leukemia

Interventions

DRUG: Ruxolitinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]